The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for relacorilant to treat patients with Cushing syndrome (hypercortisolism).
Hallmark symptoms of Cushing disease, including abdominal striae and facial rounding, were more common among younger patients than older patients.
Zacks.com on MSN2d
Corcept Shares Rise More Than 55% in 6 Months: Here's WhyCORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well ...
Corcept is studying relacorilant in a variety of serious disorders in addition to endogenous hypercortisolism (Cushing’s ...
Pferde wechseln ihr Fell je nach Jahreszeit – ein dicker Winterpelz schützt vor Kälte, während im Sommer ein kürzeres Fell ...
Das polyzystische Ovarialsyndrom ist keine Erkrankung ausschließlich junger Frauen und endet nicht mit der Menopause. Es ist mehr als eine ...
Experts broke down the factors that can increase your risk of developing stretch marks and gave The Post a rundown of ...
CNET on MSN3d
Best Supplements to Reduce Cortisol: We Asked Experts if Supplements Can Really Lower StressSupplements to reduce cortisol have been rising in popularity. They claim to lower stress levels. Are they legit?
Corcept's new drug, relacorilant, shows promise with positive Phase 3 results and an FDA decision expected. Learn more about ...
Corcept Therapeutics (CORT) announced that the FDA filed its New Drug Application (NDA) submission for its proprietary, selective cortisol ...
William Guyer, Chief Development Officer bei Corcept Therapeutics Inc. (NASDAQ: CORT ), hat den Verkauf von 20.000 Unternehmensaktien gemeldet. Der Verkauf hatte einen Gesamtwert von etwa 1,18 Million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback